Survival comparison of hepatocellular carcinoma patients treated with radioembolization versus nonoperative/interventional treatment

摘要

Aim: To compare the overall survival (OS) and liver cancer-specific survival of advanced-stage hepatocellular carcinoma (HCC) patients who received transarterial radioembolization (TARE) with those who received nonoperative/interventional treatment (NOT). Materials & methods: A total of 12,520 HCC patients from the Surveillance, Epidemiology and End Results database were categorized by treatment with either radioembolization or NOT. Kaplan-Meier and multivariate Cox regression were conducted. Results: The TARE group had both a significantly longer median overall survival than the NOT group (TARE = 9 months; NOT = 2 months; p 0.0001) and a significantly higher probability of liver cancer-specific survival (hazard ratio = 0.474). Conclusion: TARE appears to provide a significant survival advantage over the NOT population in advanced HCC patients.